Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Karen Veale"'
Autor:
Wayne C. Widdison, Ravi V.J. Chari, John M. Lambert, Hans K. Erickson, Qifeng Qiu, Rui Wu, Paulin Salomon, Rabih Gabriel, Anna Skaletskaya, Juliet A. Costoplus, Karen Veale, Leanne Lanieri, Jennifer A. Coccia, Gregory E. Jones, Ling Dong, Nathan Fishkin, E. Erica Hong, Katharine C. Lai, Yelena V. Kovtun, Jose Ponte, Yulius Y. Setiady, Rajeeva Singh
Supplementary Methods (S1-S3). Supplementary Method S1: Synthesis of di-, tri-, tetra-glycyl, and valine-citrulline-glycine peptide linkers and catabolites. Supplementary Method S2: Test of in vitro cytotoxicity, cell-cycle inhibition, and bystander
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45b6d4b4f9c44ca6353724746b9d8c98
https://doi.org/10.1158/1535-7163.22503028.v1
https://doi.org/10.1158/1535-7163.22503028.v1
Autor:
Wayne C. Widdison, Ravi V.J. Chari, John M. Lambert, Hans K. Erickson, Qifeng Qiu, Rui Wu, Paulin Salomon, Rabih Gabriel, Anna Skaletskaya, Juliet A. Costoplus, Karen Veale, Leanne Lanieri, Jennifer A. Coccia, Gregory E. Jones, Ling Dong, Nathan Fishkin, E. Erica Hong, Katharine C. Lai, Yelena V. Kovtun, Jose Ponte, Yulius Y. Setiady, Rajeeva Singh
Supplementary Table S1: Amounts of catabolites generated upon treatment of cancer cells with CX and SMCC ADCs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f1bbdc7f0c64a9492add2e343489150
https://doi.org/10.1158/1535-7163.22503025.v1
https://doi.org/10.1158/1535-7163.22503025.v1
Autor:
Wayne C. Widdison, Ravi V.J. Chari, John M. Lambert, Hans K. Erickson, Qifeng Qiu, Rui Wu, Paulin Salomon, Rabih Gabriel, Anna Skaletskaya, Juliet A. Costoplus, Karen Veale, Leanne Lanieri, Jennifer A. Coccia, Gregory E. Jones, Ling Dong, Nathan Fishkin, E. Erica Hong, Katharine C. Lai, Yelena V. Kovtun, Jose Ponte, Yulius Y. Setiady, Rajeeva Singh
Supplementary Figures (S1-S4). Supplementary Figure S1: In vitro cytotoxic activities of tetraglycyl (Gly4), triglycyl (Gly3), diglycyl (Gly2), and valine-citrulline-glycine (VCG)-linked anti-EGFR ADCs and a triglycyl-linked non-binding antibody ADC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43dfc500f111def02ff705de4c140fe0
https://doi.org/10.1158/1535-7163.22503031.v1
https://doi.org/10.1158/1535-7163.22503031.v1
Autor:
Yulius Setiady, Wei Li, Olga Ab, Kerstin Sinkevicius, Wayne C. Widdison, Lintao Wang, Stephen M. Abbott, Thomas A. Keating, Jenny Lee, Qifeng Qiu, Juliet Costoplus, Erin K. Maloney, Janet Lau, Somsinee Wisitpitthaya, Helen L. Evans, Anna Skaletskaya, Ravi V. J. Chari, Karen Veale
Publikováno v:
ACS Medicinal Chemistry Letters
Antibody–drug conjugates (ADCs) that incorporate the exatecan derivative DXd in their payload are showing promising clinical results in solid tumor indications. The payload has an F-ring that also contains a second chiral center, both of which comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e42242bac68acbee915c5172bc9f7949
https://doi.org/10.1021/acsmedchemlett.9b00301
https://doi.org/10.1021/acsmedchemlett.9b00301
Autor:
Juliet Costoplus, Jose F. Ponte, Yulius Setiady, Qifeng Qiu, Leanne Lanieri, Laura M. Bartle, Olga Ab, Kate Lai, Anna Skaletskaya, Ravi V. J. Chari, Wayne C. Widdison, Karen Veale, Yelena Kovtun, Paulin Salomon, Erin K. Maloney, Rui Wu, Ling Dong
Publikováno v:
ACS Medicinal Chemistry Letters
A new type of antibody-drug conjugate (ADC) has been prepared that contains a sulfur-bearing maytansinoid attached to an antibody via a highly stable tripeptide linker. Once internalized by cells, proteases in catabolic vesicles cleave the peptide of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70d71e22f9e1bd877ff886786ba2c7e1
https://pubmed.ncbi.nlm.nih.gov/31620224
https://pubmed.ncbi.nlm.nih.gov/31620224
Autor:
Juliet Costoplus, Barbara A. Leece, Karen Veale, Yelena Kovtun, Laura M. Bartle, Ravi V. J. Chari, Charlene Audette, Wayne C. Widdison, Gregory T. Jones, Sharon D. Wilhelm
Publikováno v:
Molecular Pharmaceutics. 12:1762-1773
Several antibody-maytansinoid conjugates (AMCs) are in clinical trials for the treatment of various cancers. Each of these conjugates can be metabolized by tumor cells to give cytotoxic maytansinoid metabolites that can kill targeted cells. In precli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5271374ef9ba18f4c17862df6bda89c9
https://doi.org/10.1021/mp5007757
https://doi.org/10.1021/mp5007757
Autor:
Rui Wu, Leanne Lanieri, Qifeng Qiu, Ravi V. J. Chari, Juliet Costoplus, Yulius Setiady, Rabih Gabriel, E. Erica Hong, Ling Dong, Yelena Kovtun, Nathan Fishkin, Karen Veale, Gregory E. Jones, Wayne C. Widdison, Rajeeva Singh, John M. Lambert, Jose F. Ponte, Katharine C. Lai, Paulin Salomon, Jennifer A. Coccia, Anna Skaletskaya, Hans K. Erickson
Publikováno v:
Molecular cancer therapeutics. 15(6)
A triglycyl peptide linker (CX) was designed for use in antibody–drug conjugates (ADC), aiming to provide efficient release and lysosomal efflux of cytotoxic catabolites within targeted cancer cells. ADCs comprising anti-epithelial cell adhesion mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa47784e9c15460281c49bb05ab3003a
https://pubmed.ncbi.nlm.nih.gov/27197308
https://pubmed.ncbi.nlm.nih.gov/27197308
Autor:
Qifeng Qiu, Yulius Setiady, Ling Dong, Juliet Costoplus, Karen Veale, Jennifer A. Coccia, Anna Skaletskaya, Paulin Salomon, Jose F. Ponte, Nathan Fishkin, Rajeeva Singh, Wayne C. Widdison, Yelena Kovtun, Charlene Audette, Ravi V. J. Chari, Luke Harris, Sharon D. Wilhelm, E. Erica Hong, Rui Wu, Erin K. Maloney, Leanne Lanieri
Publikováno v:
Bioconjugate chemistry. 26(11)
Antibody anilino maytansinoid conjugates (AaMCs) have been prepared in which a maytansinoid bearing an aniline group was linked through the aniline amine to a dipeptide, which in turn was covalently attached to a desired monoclonal antibody. Several
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::967827d953ecf59eed3fdf402f0f68a8
https://pubmed.ncbi.nlm.nih.gov/26355774
https://pubmed.ncbi.nlm.nih.gov/26355774
Autor:
Leanne Lanieri, Juliet Costoplus, Rajeeva Singh, Ling Dong, Charlene Audette, Yulius Setiady, Nathan Fishkin, Ravi V. J. Chari, Jennifer A. Coccia, Rui Wu, Greg Jones, Anja Skaletskaya, Joe Ponte, Karen Veale, Andre Dandeneau, Erin K. Maloney, Sharon D. Wilhelm, Wayne C. Widdison, Luke Harris, Yelena Kovtun
Publikováno v:
Cancer Research. 74:1618-1618
A number of ADCs consisting of a maytansinoid cytotoxic agent linked to an antibody via a cleavable disulfide linker or a non-cleavable thioether linker are in the clinic. In preclinical models, antibody-maytansinoid conjugates (AMCs) utilizing a cle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4765b64cbdaf2e7f58686cd9547e76e
https://doi.org/10.1158/1538-7445.am2014-1618
https://doi.org/10.1158/1538-7445.am2014-1618
Autor:
Erica Hong, Yulius Setiady, Jennifer A. Coccia, Nathan Fishkin, Ravi V. J. Chari, Yelena Kovtun, Rajeeva Singh, Juliet Bouchard, Hans K. Erickson, Karen Veale, Wayne C. Widdison, Jose F. Ponte, Katharine C. Lai, Andre Dandeneau, Leanne Lanieri, Gregory T. Jones
Publikováno v:
Molecular Cancer Therapeutics. 12:C164-C164
Clinical-stage ADCs with a maytansinoid cytotoxic moiety (AMCs) currently use either a cleavable, hindered disulfide linker or the non-cleavable, thioether linker, SMCC. Both types of linkers have demonstrated comparative advantages pre-clinically fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f05f56c6c8d2f40362826ba6150710d
https://doi.org/10.1158/1535-7163.targ-13-c164
https://doi.org/10.1158/1535-7163.targ-13-c164